Preliminary result of the subsequent offering

Preliminary counts indicate that DiaGenic has received subscriptions for approximately 92,738,974 shares in the subsequent offering closed yesterday. This represents approximately 155 percent of the total number of offered shares in the subsequent offering. Allocation of offer shares to the subscribers is expected to be resolved by the board of directors of DiaGenic on or about 23 November 2010.

Reference is made to the stock exchange notice dated 3 November 2010 and the prospectus dated 2 November 2010 regarding a subsequent offering of up to 60,000,000 offer shares in DiaGenic ASA (“DiaGenic” or the “Company”), each with a nominal value of NOK 0.05, at a subscription price of NOK 0.50 per share with subscription rights for shareholders of the Company as of 6 October 2010, except shareholders who were allocated shares in the private placement completed on 6 October 2010.

The subscription period for the subsequent offering expired yesterday, 17 November, 2010 at 17:30 (CET). By the end of the subscription period, preliminary counts indicate that DiaGenic has received subscriptions for approximately 92,738,974 shares. This represents approximately 155 percent of the total number of offered shares in the subsequent offering.

Allocation of offer shares to the subscribers is expected to be resolved by the board of directors of DiaGenic on or about 23 November 2010, following settlement of trading in the subscription rights in the VPS, in accordance with the allocation criteria set out in the prospectus. The final result of the subsequent offering is expected to be published through Oslo Børs’ information system on or about 23 November2010 and notifications of allocated shares and the corresponding subscription amount to be paid by each subscriber are expected to be distributed in letters from VPS on or about the same date. The payment date for the allocated shares is 26 November 2010.

The offer shares to be issued in the subsequent offering will not be tradable until the shares have been fully paid and the share capital increase has been registered in the Norwegian Register of Business Enterprises.

DnB NOR Markets acted as manager in the subsequent offering.

Contact:

Erik Christensen, CEO

Telephone: 47 95939918

e-mail: erik.christensen@diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com